Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Southwest Airlines Co — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Southwest Airlines Co trades at $45.71 (market cap $21.97B). The key difference: Southwest Airlines Co is far larger — about 2.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Southwest Airlines Co pays a 1.6% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | LUV | |
|---|---|---|
Market Cap | $9.39B | $21.97B |
Sector | Health | Industrials |
52-Week High | $356.25 | $54.80 |
52-Week Low | $241.71 | $29.67 |
Enterprise Value | $9.14B | $25.06B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Southwest Airlines (LUV) trades at $47.05, up 0.23% today, with a bullish technical signal and consensus price target of $53.86. Recent Q2 2026 earnings beat expectations with EPS of $0.94 versus $0.51 expected, driven by record revenue. The company maintains a solid liquidity position of $8.73B cash and has declared quarterly dividends of $0.18 per share, with new board appointments signaling strategic focus.
Outlook is positive with projected 2026 net income margin of 2.78% and revenue growth to $30.1B, but risks include fuel cost volatility and competitive pressures. Analyst sentiment is mixed with 42% buy ratings, offering potential upside of 14.5% to the consensus target, though institutional selling by firms like Elliott Management warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
